A091802 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)
This phase II trial studies how well avelumab with or without cetuximab work in treating patients with skin squamous cell cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
This is a "Just in Time" study. This means that it will take 7-10 days before IRB approval and consent form are available for use. Please contact the CRA so that the process can begin as soon as possible prior to the time the consent needs to be presented.
- Missouri Baptist Medical Center
- MBMC, Brandi Koziatek, 314-996-5898
View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.